These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2693012)

  • 1. Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection.
    Berger M; Rodbard D
    Diabetes Care; 1989; 12(10):725-36. PubMed ID: 2693012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacodynamic approach to optimizing insulin therapy.
    Berger MP; Rodbard D
    Comput Methods Programs Biomed; 1991 Apr; 34(4):241-53. PubMed ID: 1873991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects.
    Bantle JP; Neal L; Frankamp LM
    Diabetes Care; 1993 Dec; 16(12):1592-7. PubMed ID: 8299455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DIABLOG: a simulation program of insulin-glucose dynamics for education of diabetics.
    Biermann E; Mehnert H
    Comput Methods Programs Biomed; 1990; 32(3-4):311-8. PubMed ID: 2249430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption kinetics and action profiles after sequential subcutaneous administration of human soluble and lente insulin through one needle.
    Bilo HJ; Heine RJ; Sikkenk AC; van der Meer J; van der Veen EA
    Diabetes Care; 1987; 10(4):466-9. PubMed ID: 3304896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group.
    Kelley DE; Henry RR; Edelman SV
    Diabetes Care; 1996 Nov; 19(11):1237-42. PubMed ID: 8908387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of a glucose appearance function from foods using deconvolution.
    Yates TL; Fletcher LR
    IMA J Math Appl Med Biol; 2000 Jun; 17(2):169-84. PubMed ID: 10994512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
    Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
    Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward Better Understanding of Insulin Therapy by Translation of a PK-PD Model to Visualize Insulin and Glucose Action Profiles.
    Schneck K; Tham LS; Ertekin A; Reviriego J
    J Clin Pharmacol; 2019 Feb; 59(2):258-270. PubMed ID: 30339268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fuzzy-based controller for glucose regulation in type-1 diabetic patients by subcutaneous route.
    Campos-Delgado DU; Hernández-Ordoñez M; Femat R; Gordillo-Moscoso A
    IEEE Trans Biomed Eng; 2006 Nov; 53(11):2201-10. PubMed ID: 17073325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous insulin substitution in insulin-dependent diabetes mellitus. Pharmacokinetic and pharmacodynamic studies.
    Olsson PO
    Acta Med Scand Suppl; 1987; 718():1-78. PubMed ID: 3321929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-insulin regulation model with subcutaneous insulin injection and evaluation using diabetic inpatients data.
    Wu Z; Chui CK; Hong GS; Khoo E; Chang S
    Comput Methods Programs Biomed; 2013 Aug; 111(2):347-56. PubMed ID: 23756090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalization of plasma glucose of unstable diabetes: studies under ambulatory, fed conditions with pumped intravenous insulin.
    Service FJ
    J Lab Clin Med; 1978 Mar; 91(3):480-9. PubMed ID: 627751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
    Olsson PO; Hans A; Henning VS
    Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models of subcutaneous insulin kinetics. A critical review.
    Nucci G; Cobelli C
    Comput Methods Programs Biomed; 2000 Jul; 62(3):249-57. PubMed ID: 10837910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen.
    Rabasa-Lhoret R; Garon J; Langelier H; Poisson D; Chiasson JL
    Diabetes Care; 1999 May; 22(5):667-73. PubMed ID: 10332663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.